LUNG Company Profile and Key Details

Q: Who are the executives of LUNG?

Mr. David A. LehmanGen. Counsel & Sec.Ms. Lisa PaulChief People OfficerMr. Sri RadhakrishnanChief Technical OfficerMr. Geoffrey Beran RoseChief Commercial OfficerMs. Marcee M. MaroneyVice President of MarketingMr. Jérôme ErathSenior Vice President & GM of Europe Middle-East & AfricaSarah HuberVice President of Sales (U.S.)Dr. Derrick Sung Ph.D.Chief Financial OfficerMs. Lauren CristinaVice President of Fin. & Admin. (U.S.)Mr. Glendon E. FrenchChief Executive Officer, Pres & Director

NASDAQ : LUNG

Pulmonx

$1.98

0.03+1.54%

At Close 4:00 PM

56.79

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pulmonx Corporation (LUNG) stock surged +1.54%, trading at $1.98 on NASDAQ, up from the previous close of $1.95. The stock opened at $2.01, fluctuating between $1.97 and $2.02 in the recent session.

Stock Snapshot

1.95

Prev. Close

83.63M

Market Cap

1.97

Day Low

-1.71

P/E Ratio

-1.16

EPS (TTM)

-1

Cash Flow per Share

2.01

Open

42.24M

Number of Shares

2.02

Day High

97.34%

Free Float in %

3.08

Book Value

264.02K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 17, 2026	2.01	2.02	1.97	1.98	264.02K
Sep 16, 2026	2.04	2.04	1.88	1.95	232.17K
Sep 15, 2026	1.94	1.99	1.91	1.91	228.78K
Sep 14, 2026	1.83	2.00	1.83	1.97	292.84K
Sep 11, 2026	1.94	2.01	1.82	1.85	204.86K
Sep 10, 2026	1.90	1.91	1.82	1.85	479.33K
Sep 09, 2026	2.12	2.16	1.98	1.98	451.87K
Sep 08, 2026	2.18	2.19	2.07	2.08	307.84K
Sep 04, 2026	2.26	2.30	2.19	2.21	220.38K
Sep 03, 2026	2.27	2.33	2.25	2.26	284.13K
Sep 02, 2026	2.24	2.44	2.24	2.28	407.39K
Sep 01, 2026	2.26	2.43	2.23	2.24	524.8K
Aug 31, 2026	2.34	2.39	2.30	2.38	320.01K
Aug 28, 2026	2.42	2.51	2.38	2.38	277.21K
Aug 27, 2026	2.50	2.59	2.41	2.42	268.63K
Aug 26, 2026	2.54	2.59	2.37	2.50	312.7K
Aug 25, 2026	2.29	2.52	2.28	2.50	581.65K
Aug 24, 2026	2.24	2.35	2.21	2.28	393.76K
Aug 21, 2026	2.30	2.35	2.19	2.26	610.13K
Aug 20, 2026	2.28	2.39	2.28	2.30	395.43K

Contact Details

Redwood City, CA 94063

United States

https://pulmonx.com 650 364 0400

About Company

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Stock Peers

BRKRP

17.2+3.85%

Bruker Corporation$464.27 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 UFPT

-4-1.43%

UFP Technologies, Inc.$275.41 MASI

Masimo Corporation$179.95 ALGN

-0.74-0.49%

Align Technology, Inc.$149.71 PODD

0.95+0.68%

Insulet Corp.$141.55 IRTC

-0.06999969-0.06%

iRhythm Technologies, Inc.$111.75 DXCM

0.59+0.68%

DexCom, Inc.$87.93 TMDX

-0.9-1.03%

TransMedics Group, Inc.$86.66 IRMD

0.16+0.19%

IRadimed Corporation$82.74

Company Overview

Pulmonx Corporation (NASDAQ:LUNG) closed at $1.98 USD, gaining $0.03 (1.54%) from the previous close of $1.95. The stock is currently mid-range between its 52-week high and low $1.13 and $2.89. With a market capitalization of about $83.63 million, Pulmonx Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.28). Key stats such as the average daily volume over the past year has been around 578.57 thousand shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Pulmonx Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Glendon E. French, the company employs approximately 296 people and listed since October 01, 2020. Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 7.84%, SMA50 -13.11%, SMA200 -22.71%). The stock’s 14-day RSI is 51.38 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.4% below its high and over 25.19% above its low. Average 10-day trading volume of 307.71 thousand shares is below the 3-month average of 568.28 thousand, indicating normal recent market interest.

Valuation Metrics

Pulmonx Corporation trades at a P/E ratio of -1.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.96 and a price-to-book ratio of 2.14 suggesting the stock is closer to book value. The P/FCF stands at -2.73, also above market averages.

Dividend & Fair Value

Pulmonx Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.39. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Pulmonx Corporation generated EPS of -$1.41 over the past year. Five-year average earnings growth is -19.8%. Wall Street analysts project EPS growth of 14.12% annually over the next five years. The latest quarter delivered EPS of -$0.24. The next quarter is forecast at -$0.39. Next year's EPS is expected at $3.52. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $4.00. The high target offers 607.07% upside. The low target suggests 102.02% downside. The mean target is $11.43. This offers 477.27% upside. Pulmonx Corporation earnings surprise history is frequent misses against expectations. The quarter that ended July 29, 2026, missed forecasts by -14.29%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -2.7% in April 30, 2025.

Shareholding & Insider Activity

Pulmonx Corporation has 42.95 million shares outstanding. The public float is 37.70 million shares, elevated short interest at 2.92% of float. This equals 1.06 million shares. The short ratio is 2.12 days. Institutional investors hold 82.69% of the float. Insiders own 4.89%. French Glendon E. III holds 1.14 million shares, Rose Geoffrey Beran has 449.83 thousand shares and Sung Derrick has 391.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 50.22 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Pulmonx generated $68.68M in revenue, or $1.81 per share. Gross margin was 73.32%, operating margin -90.19%, and net profit margin -88.60%. Returns are negative, with ROA at -34.00% and ROE at -51.42%.
On valuation metrics, Pulmonx trades at a P/E of -1.73, P/S of 0.96 and P/B of 2.14. The current ratio is 4.32 and quick ratio is 3.52. Operationally, the company’s inventory turnover is 1.22 and cash conversion cycle is 264.25 days. Debt-to-equity is 1.43, supported by a cash flow-to-debt ratio of -0.54.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pulmonx posted revenue of $68.68M, down slightly from $53.66M in the prior quarter. Gross profit was $50.35M (margin 73.32%). Operating income was - $61.94M (margin -90.2%). Net income was- $60.84M (EPS - $1.60).
The company ended the quarter with $117.34M in cash and short-term investments, a total debt of $41.42M, and net debt of - $42.36M. Total assets were $178.95M, with equity of $118.32M. Financials further reflected weakness, with operating cash flow of - $37.61M, free cash flow of - $38.42M, and capital expenditures of - $807.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Pulmonx Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.01%, with price expected at $1.96 by September 30, 2026, within a range of $1.66 to $2.27 3-Month Outlook: Projected rise of 321.72%, reaching $8.35 by December 15, 2026, with a range of $8.13 to $8.59. 1-Year Outlook: Projected gain of 303.54%, with price at $7.99 by September 16, 2027, within a range of $0.00 to $9.14.

Key Takeaways

Pulmonx Corporation (NASDAQ:LUNG) shares are down -19.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pulmonx Corporation trading at a premium to the broader market with a P/E of -1.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.53, suggesting 785.35% upside. Our AI forecast model points to short-term weakness (-1.01% over two weeks), a medium-term rise (321.72% over three months), and a longer-term gain (303.54% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Pulmonx Corporation (LUNG) stock price?

Pulmonx Corporation (NASDAQ: LUNG) stock price is $1.98 in the last trading session. During the trading session, LUNG stock reached the peak price of $2.02 while $1.97 was the lowest point it dropped to. The percentage change in LUNG stock occurred in the recent session was 1.54% while the dollar amount for the price change in LUNG stock was $0.03.

LUNG's industry and sector of operation?

The NASDAQ listed LUNG is part of Medical - Devices industry that operates in the broader Healthcare sector. Pulmonx Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LUNG?

Mr. David A. Lehman
Gen. Counsel & Sec.
Ms. Lisa Paul
Chief People Officer
Mr. Sri Radhakrishnan
Chief Technical Officer
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Ms. Marcee M. Maroney
Vice President of Marketing
Mr. Jérôme Erath
Senior Vice President & GM of Europe Middle-East & Africa
Sarah Huber
Vice President of Sales (U.S.)
Dr. Derrick Sung Ph.D.
Chief Financial Officer
Ms. Lauren Cristina
Vice President of Fin. & Admin. (U.S.)
Mr. Glendon E. French
Chief Executive Officer, Pres & Director

How LUNG did perform over past 52-week?

LUNG's closing price is 75.22% higher than its 52-week low of $1.13 where as its distance from 52-week high of $2.89 is -31.49%.

How many employees does LUNG have?

Number of LUNG employees currently stands at 296.

Link for LUNG official website?

Official Website of LUNG is: https://pulmonx.com

How do I contact LUNG?

LUNG could be contacted at phone 650 364 0400 and can also be accessed through its website. LUNG operates from 700 Chesapeake Drive, Redwood City, CA 94063, United States.

How many shares of LUNG are traded daily?

LUNG stock volume for the day was 264.02K shares. The average number of LUNG shares traded daily for last 3 months was 578.57K.

What is the market cap of LUNG currently?

The market value of LUNG currently stands at $83.63M with its latest stock price at $1.98 and 42.24M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	296
Beta	0.28
Sales or Revenue	$68.68M
5Y Sales Change%	0.872%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

LUNG Company Profile and Key Details

Pulmonx

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Company Overview

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways